Absci (ABSI) Accumulated Expenses (2020 - 2025)
Absci (ABSI) posted Accumulated Expenses of $8.2 million for Q3 2025, up 43.99% sequentially from $5.7 million in Q2 2025, and down 54.9% YoY from $18.2 million in Q3 2024.
Analysis
Absci (ABSI) Accumulated Expenses (2020 - 2025) Analysis & Trends
Absci has reported Accumulated Expenses for 6 years, with the latest figure at $8.2 million in Q3 2025.
- Quarterly Accumulated Expenses fell 54.9% year-over-year to $8.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $8.2 million (down 54.9% YoY) and the FY2024 annual result came in at $6.8 million, up 4.41% from the prior year.
- Accumulated Expenses rose to $8.2 million in Q3 2025 per ABSI's latest filing, from $5.7 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $25.6 million in Q1 2022 and troughed at $4.3 million in Q1 2025.
- A 5-year average of $14.9 million and a median of $16.8 million in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2025: Accumulated Expenses jumped 1011.15% in 2021, then slumped 72.36% in 2025.
- Over 5 years, Accumulated Expenses stood at $17.4 million in 2021, then gained by 17.48% to $20.5 million in 2022, then tumbled by 68.0% to $6.6 million in 2023, then increased by 4.41% to $6.8 million in 2024, then grew by 20.27% to $8.2 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $8.2 million, $5.7 million, and $4.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 8.23 Mn |
| Jun 30, 2025 | 5.72 Mn |
| Mar 31, 2025 | 4.26 Mn |
| Dec 31, 2024 | 6.84 Mn |
| Sep 30, 2024 | 18.25 Mn |
| Jun 30, 2024 | 16.85 Mn |
| Mar 31, 2024 | 15.40 Mn |
| Dec 31, 2023 | 6.55 Mn |
| Sep 30, 2023 | 19.68 Mn |
| Jun 30, 2023 | 16.71 Mn |
| Mar 31, 2023 | 18.09 Mn |
| Dec 31, 2022 | 20.48 Mn |
| Sep 30, 2022 | 20.98 Mn |
| Jun 30, 2022 | 17.05 Mn |
| Mar 31, 2022 | 25.64 Mn |
| Dec 31, 2021 | 17.43 Mn |
| Sep 30, 2021 | 15.28 Mn |
| Jun 30, 2021 | 14.00 Mn |
| Dec 31, 2020 | 1.57 Mn |